Respect
We treat everyone with dignity and professionalism.
Company
Built to uncover overlooked biology.
TenSixty brings together platform biology, computation, and biologics discovery to turn overlooked tumor-selective epitopes into new therapeutic possibilities.
Our mission
Expand what oncology can target.
We are building a multi-asset oncology company around the hypothesis that epitope context can shape therapeutic selectivity.
The same protein can present fundamentally different therapeutic opportunities in tumor and healthy tissue. By discovering those differences, we aim to create medicines with a wider therapeutic window.
Our values
Ambitious science, grounded in how we work.
Our work spans disciplines and depends on a culture where rigor, collaboration, and responsibility reinforce one another.
Teamwork
We work as one team and look out for each other.
Impact
We pursue ambitious goals with rigor and determination.
Our people
Experience across biology, computation, and drug development.
Our leadership is supported by a board and advisory team with experience across oncology, ADCs, biologics discovery, clinical development, bioconjugation, and toxicology.
Leadership
Founding team
Daniel Montoro
Chief Executive Officer
Christoph Muus
Chief Technology Officer
Karthik Jagadeesh
Chief AI OfficerBoard of Directors
Company governance
Zhen Su, MD/MBA
Chief Executive Officer & DirectorMarengo Therapeutics · Former Global Head of Oncology, Merck KGaA
Elena Viboch, MS/MBA
Managing DirectorGeneral Catalyst
Sara Choi, MBA
PartnerWing Venture Capital
Scientific & Clinical Advisors
Discovery to development
John Lambert, PhD
ADC Discovery & DevelopmentIndependent biotechnology consultant · Former EVP, Research & CSO, ImmunoGen
Wendy Young, PhD
Small-Molecule Drug DiscoveryAdvisor, GV · Former SVP, Small Molecule Drug Discovery, Genentech
Richard Gregory, PhD
Biologics & ADC DiscoveryIndependent biopharma consultant · Former EVP & CSO, ImmunoGen
Stephen Gould, PhD
ADC & T-cell Engager DevelopmentFormer CSO, Atreca · Former Executive Director, Translational Oncology, Genentech
Alessandra Cesano, MD/PhD
Clinical DevelopmentCatalyst Advisor, General Catalyst · Former CMO, ESSA Pharma
Ovid Trifan, MD/PhD
Clinical DevelopmentSenior Partner, Bracken · Chief Medical Officer, Iterion Therapeutics
Hans Erickson, PhD
ADC & BioconjugationFormer ADC leader at ImmunoGen and Genentech
Lolke de Haan, PhD
Nonclinical Safety & ToxicologyIndependent consultant · Former VP, Toxicology, ADC Therapeutics
Join TenSixty